@article{MTMT:34728591,
	title = {A mikrobiom és a kardiovaszkuláris egészség},
	url = {https://m2.mtmt.hu/api/publication/34728591},
	author = {Péterfi, Zoltán},
	doi = {10.26430/CHUNGARICA.2024.54.1.32},
	journal-iso = {CARDIOL HUNG},
	journal = {CARDIOLOGIA HUNGARICA},
	volume = {54},
	unique-id = {34728591},
	issn = {0133-5596},
	abstract = {A bél mikrobiom fontos szerepet játszik számos betegség kialakulásában vagy annak progressziójában. Egy kevésbé ismert terület a kardiovaszkuláris rendszer betegségei és a mikrobiom közötti kapcsolat, a bél–szív tengely és ateroszklerózis kapcsolata. A bél mikrobiom hatását különböző közvetítő molekulákon, mint a lipopoliszacharid, trimetilamin, fenilactetil-glutamin, rövid szénláncú zsírsavak, másodlagos epesavak, keresztül fejti ki. A legtöbb hatás, nem közvetlen, hanem az anyagcsere-folyamatok megváltoztatásán keresztül érvényesül és tartós folyamat eredménye, ezért vizsgálata és az összefüggések bizonyítása is nehézségekbe ütközik. A bél mikrobiom egyensúlyának helyreállítása segíthet a kóros folyamatok megállításában vagy azok visszafordításában. Jelen közleményben összefoglaljuk az eddigi ismereteinket a mikrobiom anyagcseretermékeinek kardiovaszkuláris rendszerre való hatásáról, valamint a rendelkezésünkre álló lehetőségeket a kóros hatások kivédése érdekében.},
	year = {2024},
	eissn = {1588-0230},
	pages = {32-38},
	orcid-numbers = {Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:34398321,
	title = {The Role of the Intestinal Microbiome in Multiple Sclerosis—Lessons to Be Learned from Hippocrates},
	url = {https://m2.mtmt.hu/api/publication/34398321},
	author = {El-Sayed, Mohamed Mahmoud and Mohak, Sidhesh and Gala, Dhir and Fabian, Reka and Péterfi, Zoltán and Fabian, Zsolt},
	doi = {10.3390/biology12121463},
	journal-iso = {BIOLOGY-BASEL},
	journal = {BIOLOGY-BASEL},
	volume = {12},
	unique-id = {34398321},
	abstract = {Based on recent advances in research of chronic inflammatory conditions, there is a growing body of evidence that suggests a close correlation between the microbiota of the gastrointestinal tract and the physiologic activity of the immune system. This raises the idea that disturbances of the GI ecosystem contribute to the unfolding of chronic diseases including neurodegenerative pathologies. Here, we overview our current understanding on the putative interaction between the gut microbiota and the immune system from the aspect of multiple sclerosis, one of the autoimmune conditions accompanied by severe chronic neuroinflammation that affects millions of people worldwide.},
	year = {2023},
	eissn = {2079-7737},
	orcid-numbers = {Mohak, Sidhesh/0009-0006-5917-4680; Gala, Dhir/0000-0003-1410-8576; Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:34306768,
	title = {Löffler endokarditisz talaján kialakult infektív endokarditisz esete},
	url = {https://m2.mtmt.hu/api/publication/34306768},
	author = {Rábai, Miklós and Sándor, Barbara and Magyar, Klára and Kenyeres, Péter and Várady, Edit and Tóth, Levente and Márton, Zsolt and Péterfi, Zoltán and Szabados, Eszter and Huszár, Judit and Tóth, Kálmán and Habon, Tamás and Halmosi, Róbert},
	journal-iso = {CARDIOL HUNG},
	journal = {CARDIOLOGIA HUNGARICA},
	volume = {53},
	unique-id = {34306768},
	issn = {0133-5596},
	year = {2023},
	eissn = {1588-0230},
	pages = {A339-A339},
	orcid-numbers = {Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:34276104,
	title = {A Belügyminisztérium egészségügyi szakmai irányelve az epeút- és epehólyag-gyulladás diagnosztikus kritériumairól és terápiájáról. Klinikai egészségügyi szakmai irányelv},
	url = {https://m2.mtmt.hu/api/publication/34276104},
	author = {Czakó, László and Dubravcsik, Zsolt and Gyökeres, Tibor and Hritz, István and Illés, Dóra and Madácsy, László and Nagy, András and Péterfi, Zoltán and Szepes, Zoltán and Szücs, Ákos and Vincze, Áron},
	journal-iso = {EGÉSZSÉGÜGYI KÖZLÖNY},
	journal = {EGÉSZSÉGÜGYI KÖZLÖNY},
	volume = {73},
	unique-id = {34276104},
	issn = {2063-1146},
	year = {2023},
	pages = {898-936},
	orcid-numbers = {Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:34095174,
	title = {Migraine as a Disease Associated with Dysbiosis and Possible Therapy with Fecal Microbiota Transplantation},
	url = {https://m2.mtmt.hu/api/publication/34095174},
	author = {Kappéter, Ágnes and Sipos, Dávid and Varga, Adorján and Vigvári, Szabolcs József and Halda-Kiss, Bernadett and Péterfi, Zoltán},
	doi = {10.3390/microorganisms11082083},
	journal-iso = {MICROORGANISMS},
	journal = {MICROORGANISMS},
	volume = {11},
	unique-id = {34095174},
	issn = {2076-2607},
	abstract = {Migraine is a painful neurological condition characterized by severe pain on one or both sides of the head. It may be linked to changes in the gut microbiota, which are influenced by antibiotic use and other factors. Dysbiosis, which develops and persists as a result of earlier antibiotic therapy, changes the composition of the intestinal flora, and can lead to the development of various diseases such as metabolic disorders, obesity, hematological malignancies, neurological or behavioral disorders, and migraine. Metabolites produced by the gut microbiome have been shown to influence the gut–brain axis. The use of probiotics as a dietary supplement may reduce the number and severity of migraine episodes. Dietary strategies can affect the course of migraines and are a valuable tool for improving migraine management. With fecal microbiota transplantation, gut microbial restoration is more effective and more durable. Changes after fecal microbiota transplantation were studied in detail, and many data help us to interpret the successful interventions. The microbiological alteration of the gut microflora can lead to normalization of the inflammatory mediators, the serotonin pathway, and influence the frequency and intensity of migraine pain.},
	year = {2023},
	eissn = {2076-2607},
	orcid-numbers = {Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:34025825,
	title = {A széklettranszplantáció aktuális hazai helyzete},
	url = {https://m2.mtmt.hu/api/publication/34025825},
	author = {Péterfi, Zoltán and Varga, Adorján and Vigvári, Szabolcs József and Sipos, Dávid},
	doi = {10.33570/CEUJGH.9.2.59},
	journal-iso = {CENT EUR J GASTRO HEPATOL},
	journal = {CENTRAL EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY / GASZTROENTEROLÓGIAI ÉS HEPATOLÓGIAI SZEMLE},
	volume = {9},
	unique-id = {34025825},
	year = {2023},
	eissn = {2415-9107},
	pages = {59-62},
	orcid-numbers = {Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:33842885,
	title = {Epeút- és epehólyag-gyulladás: diagnosztikus kritériumok és terápia [Cholangitis and cholecystitis: diagnostic criteria and management]},
	url = {https://m2.mtmt.hu/api/publication/33842885},
	author = {Czakó, László and Gyökeres, Tibor Zoltán and Hritz, István and Madácsy, László and Illés, Dóra and Szepes, Zoltán and Dubravcsik, Zsolt and Péterfi, Zoltán and Nagy, András and Szűcs, Ákos and Vincze, Áron},
	doi = {10.1556/650.2023.32770},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {164},
	unique-id = {33842885},
	issn = {0030-6002},
	abstract = {In developed countries, diseases of the gallbladder and the biliary tract count as some of the most frequent gastrointestinal disorders. The inflammation of the gallbladder/biliary tree is a potentially severe, even lethal condition that requires rapid diagnosis and early multidisciplinary approach to be treated. Although the frequency of these diseases is high, the treatment is not unified in Hungary yet. The aim of the evidence-based recommendation is to clarify the diagnostic criteria and severity grading of these diseases and to highlight the indications and rules of proper application of the numerous available therapeutic interventions. The recent guideline is based on the consensus of the Board members of the Endoscopic Section of the Hungarian Gastroenterology Society in contribution with renown experts of surgery, infectology as well as interventional radiology and it counts as a clear and easy applicable guide during the all-day healthcare practice. Our guidelines are based on Tokyo guidelines established on the basis of the consensus reached in the International Consensus Meeting held in Tokyo which were revised in 2013 (TG13) and in 2018 (TG18). Orv Hetil. 2023; 164(20): 770-787.},
	keywords = {Cholecystectomy; antimicrobial therapy; Acute cholecystitis; CHOLECYSTECTOMIA; antibiotikus kezelés; biliary drainage; Severity grading; acute cholangitis; akut cholangitis; akut cholecystitis; epeúti drenázs; súlyossági osztályozás},
	year = {2023},
	eissn = {1788-6120},
	pages = {770-787},
	orcid-numbers = {Czakó, László/0000-0002-6331-0802; Hritz, István/0000-0002-8763-6006; Szepes, Zoltán/0000-0002-9466-8719; Péterfi, Zoltán/0000-0001-9658-153X; Vincze, Áron/0000-0003-2217-7686}
}

@article{MTMT:33588242,
	title = {Efficacy of lyophilised bacteria-rich faecal sediment and supernatant with reduced bacterial count for treating patients with Clostridioides difficile Infection – A novel method for capsule faecal microbiota transfer},
	url = {https://m2.mtmt.hu/api/publication/33588242},
	author = {Varga, Adorján and Makszin, Lilla and Bufa, Anita and Sipos, Dávid and Kása, Péter and Pál, Szilárd and Rosenstiel, Philip and Sommer, Felix and Kocsis, Béla and Péterfi, Zoltán},
	doi = {10.3389/fcimb.2023.1041384},
	journal-iso = {FRONT CELL INFECT MI},
	journal = {FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY},
	volume = {13},
	unique-id = {33588242},
	issn = {2235-2988},
	year = {2023},
	eissn = {2235-2988},
	orcid-numbers = {Makszin, Lilla/0000-0002-9764-4763; Kása, Péter/0000-0002-6134-0928; Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:33567482,
	title = {Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme},
	url = {https://m2.mtmt.hu/api/publication/33567482},
	author = {Kanizsai, Andrea and Zavori, Laszlo and Molnár, Tihamér and Tőkés-Füzesi, Margit and Szalai, Zoltan and Berecz, Janos and Várnai, Réka and Péterfi, Zoltán and Schwarcz, Attila and Csécsei, Péter},
	doi = {10.3390/vaccines11010182},
	journal-iso = {VACCINES-BASEL},
	journal = {VACCINES (BASEL)},
	volume = {11},
	unique-id = {33567482},
	abstract = {Background: It is known that adverse reactions following SARS-CoV-2 vaccinations show a positive correlation with the subsequent antibody titer. However, it is not clear how the adverse reactions following the booster vaccination are related to the antibody levels that can be measured after a 3rd dose. The primary goal of this study was to investigate whether the adverse reactions following the booster vaccination show a correlation with subsequent antibody levels. Methods: Adverse reactions occurring within 7 days after the 3rd vaccination were recorded and the anti-SARS-CoV-2 spike protein immunoglobulin (Ig) level in the venous blood was measured on post-vaccination 14th, 60th and 120th days. Results: A total of 218 volunteers were included in the study. Main findings: (i) The adverse reactions that appeared after the booster dose did not show a positive correlation with the subsequent antibody level, except a correlation in the case of fever; (ii) there were more symptomatic patients in the group receiving heterologous booster vaccine, (iii) fever after the 2nd dose was independently associated with a reduction in the likelihood of COVID-19 positivity after the booster dose. Conclusion: No adverse reactions, but fever showed a correlation with the antibody level after the booster SARS-CoV-2 vaccine.},
	year = {2023},
	eissn = {2076-393X},
	orcid-numbers = {Zavori, Laszlo/0000-0002-1715-4167; Péterfi, Zoltán/0000-0001-9658-153X}
}

@article{MTMT:33560025,
	title = {Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct). a randomised, double-blind, placebo-controlled phase 3 trial.},
	url = {https://m2.mtmt.hu/api/publication/33560025},
	author = {Trøseid, Marius and Arribas, José R and Assoumou, Lambert and Holten, Aleksander Rygh and Poissy, Julien and Terzić, Vida and Mazzaferri, Fulvia and Baño, Jesús Rodríguez and Eustace, Joe and Hites, Maya and Joannidis, Michael and Paiva, José-Artur and Reuter, Jean and Püntmann, Isabel and Patrick-Brown, Thale D J H and Westerheim, Elin and Nezvalova-Henriksen, Katerina and Beniguel, Lydie and Dahl, Tuva Børresdatter and Bouscambert, Maude and Halanova, Monika and Péterfi, Zoltán and Tsiodras, Sotirios and Rezek, Michael and Briel, Matthias and Ünal, Serhat and Schlegel, Martin and Ader, Florence and Lacombe, Karine and Amdal, Cecilie Delphin and Rodrigues, Serge and Tonby, Kristian and Gaudet, Alexandre and Heggelund, Lars and Mootien, Joy and Johannessen, Asgeir and Møller, Jannicke Horjen and Pollan, Beatriz Diaz and Tveita, Anders Aune and Kildal, Anders Benjamin and Richard, Jean-Christophe and Dalgard, Olav and Simensen, Victoria Charlotte and Baldé, Aliou and de Gastines, Lucie and Del Álamo, Marta and Aydin, Burç and Lund-Johansen, Fridtjof and Trabaud, Mary-Anne and Diallo, Alpha and Halvorsen, Bente and Røttingen, John-Arne and Tacconelli, Evelina and Yazdanpanah, Yazdan and Olsen, Inge C and Costagliola, Dominique},
	doi = {10.1186/s13054-022-04205-8},
	journal-iso = {CRIT CARE},
	journal = {CRITICAL CARE},
	volume = {27},
	unique-id = {33560025},
	issn = {1364-8535},
	abstract = {Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants.Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, placebo-controlled trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external evidence. Patients with severe/critical COVID-19 were randomised to Baricitinib 4 mg once daily or placebo, added to standard of care. The primary endpoint was all-cause mortality within 60 days. Participants were remotely followed to day 90 for safety and patient related outcome measures.Two hundred ninety-nine patients were screened, 284 randomised, and 275 received study drug or placebo and were included in the modified intent-to-treat analyses (139 receiving baricitinib and 136 placebo). Median age was 60 (IQR 49-69) years, 77% were male and 35% had received at least one dose of SARS-CoV2 vaccine. There were 21 deaths at day 60 in each group, 15.1% in the baricitinib group and 15.4% in the placebo group (adjusted absolute difference and 95% CI - 0.1% [- 8·3 to 8·0]). In sensitivity analysis censoring observations after drug discontinuation or rescue therapy (tocilizumab/increased steroid dose), proportions of death were 5.8% versus 8.8% (- 3.2% [- 9.0 to 2.7]), respectively. There were 148 serious adverse events in 46 participants (33.1%) receiving baricitinib and 155 in 51 participants (37.5%) receiving placebo. In subgroup analyses, there was a potential interaction between vaccination status and treatment allocation on 60-day mortality. In a subsequent post hoc analysis there was a significant interaction between vaccination status and treatment allocation on the occurrence of serious adverse events, with more respiratory complications and severe infections in vaccinated participants treated with baricitinib. Vaccinated participants were on average 11 years older, with more comorbidities.This clinical trial was prematurely stopped for external evidence and therefore underpowered to conclude on a potential survival benefit of baricitinib in severe/critical COVID-19. We observed a possible safety signal in vaccinated participants, who were older with more comorbidities. Although based on a post-hoc analysis, these findings warrant further investigation in other trials and real-world studies. Trial registration Bari-SolidAct is registered at NCT04891133 (registered May 18, 2021) and EUClinicalTrials.eu ( 2022-500385-99-00 ).},
	keywords = {SAFETY; vaccination; baricitinib; COVID-19},
	year = {2023},
	eissn = {1466-609X},
	orcid-numbers = {Péterfi, Zoltán/0000-0001-9658-153X}
}